Pierwotny chłoniak OUN: badanie fazy I leku NX-5948
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Badania kliniczne prowadzone w ośrodku Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy (Ul. Wilhelma Konrada Roentgena 5, Warszawa), które rekrutują lub wkrótce zaczną rekrutację. Dane pochodzą z rejestrów badań.
250 badań: 237 rekrutuje, 13 wkrótce zacznie.
Ośrodek niezweryfikowany
Wpisz słowo, żeby przeszukać wszystkie 250 badań.
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Phase 1 Study of MK-1084 in KRAS mutant advanced solid tumors
Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer (INTRINSIC)
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated…
Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment
Radiation Free Chemotherapy for Early Hodgkin Lymphoma
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients…
A Phase 1/2 Study of DZR123 (CPI-0209) in Patients with Advanced Solid Tumors and Lymphomas
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Pan Tumor Rollover Study
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include…
Mevrometostat Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
A Phase I/II, Multi-part, Open-label, Multicenter, First-in-human Trial to Evaluate Safety, Tolerability, Immunogenicity, and Signals of Efficacy of JJP-1008 as Monotherapy and…
A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment with AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T)…
Vortosiran for VTE Prevention
Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 18 listopada 2026.